Clinical Trial Update: Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis [Phase 3]

View source ↗

Summary

This Phase 3 trial update reports on the efficacy and safety of intravenous and subcutaneous secukinumab for moderate to severe chronic plaque psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Plaque-type Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2015-03-18